Prof Terpos speaks to ecancer about carfilzomib 56mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with 8 cycles of bortezomib and dexamethasone (DVd); a matching-adjusted Indirect treatment comparison.
This study was presented at this year’s ASH conference. Prof Terpos initially speaks about the background of the study saying that lenalidomide is increasingly used for the treatment of newly diagnosed multiple myeloma.
However, most patients experience relapse during treatment or after prolonged exposure to lenalidomide, therefore, there is an emerging unmet need for new, highly efficacious lenalidomide-sparing regimens at relapse. He then highlights the key results of this trial saying that KdD was associated with a significant reduction in the risk of progression or death compared with DVd.
Prof Terpos says that the present analysis suggests that KdD improves outcomes compared with DVd in patients with RRMM and may provide a rationale for a preferential treatment. In the end, he talks about how these results can impact the future treatment of r/r multiple myeloma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.